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Preparation and Characterization of Chitosan-Coated Oleic Acid Liposomes for 
Intravenous Delivery 
(Penyediaan dan Pencirian Liposom Asid Oleik Bersalut Kitosan untuk Penghantaran Intravena)




Liposome has been studied as a potential carrier for targeting and controlled drug delivery. However, poor stability 
remains a challenge because it can lead to drug leakage from the vesicles thus reduce the effectiveness towards the 
target cell. For this aim, the present study incorporated the low molecular weight chitosan (LMWC) into the oleic acid 
liposome to maintain the stability and prolong the lifetime in the blood circulation. The thin-film hydration method 
was employed to prepare the oleic acid liposomes prior to coating them with LMWC. The stability of the liposomes was 
determined by the measurement of particle size and zeta potential for 28 days. The morphology of the liposome was 
confirmed by observing the shape under transmission electron microscopy (TEM) and it showed almost spherical in 
shape. The average particle size increased to 201.23 nm and -51.4 mV when 5 mg of LMWC was added to the oleic acid 
liposome. The increase of particle size and zeta potential of LMWC-coated liposome indicated that polymer-liposome 
interaction had changed the stability of liposome thus this invention could be useful for delivering active ingredients 
through intravenous delivery.
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ABSTRAK
Liposom sedang dikaji sebagai sebuah pengangkut yang berpotensi tinggi bagi penyasaran dan pengawalan 
penghantaran ubat. Walau bagaimanapun, mengekalkan kestabilannya merupakan satu cabaran kerana ia boleh 
menyebabkan ubat terkeluar dari vesikel serta mengurangkan keberkesanan terhadap sel yang hendak disasarkan. 
Kajian ini bermatlamat untuk menyalutkan kitosan berjisim molekul rendah ke dalam liposom asid oleik untuk 
mengekalkan kestabilan dan jangka hayatnya dalam peredaran darah. Kaedah penghidratan lapisan nipis digunakan 
untuk menghasilkan liposom asid oleik sebelum disalut dengan kitosan berjisim molekul rendah. Kestabilan liposom 
ditentukan dengan mengukur saiz zarah dan potensi zeta selama 28 hari. Morfologi liposom ditentukan dengan 
memerhatikan bentuk di bawah mikroskop elektron transmisi dan menunjukkan bentuk seakan bentuk sfera. Purata 
saiz zarah meningkat kepada 201.23 nm dan -51.4 mV apabila 5 mg kitosan telah ditambahkan ke liposom asid oleik. 
Peningkatan saiz zarah dan potensi zeta bagi liposom bersalut kitosan berjisim molekul rendah menunjukkan bahawa 
interaksi polimer dan liposom telah mengubah kestabilan liposom dan penemuan ini berpotesi untuk menyampaikan 
bahan aktif secara penghantaran intravena.
Kata kunci: Asid oleik; Itraconazole; kitosan berjisim molekul rendah; liposom
INTRODUCTION
Liposome was derived from the combination of two Greek 
words, ‘lipos’ meaning fat and ‘soma’ meaning body. It 
was first discovered by Alec D Bangham and his co-
workers in 1963 (Bangham & Horne 1964). It was invented 
to improve the effectiveness of the established drugs by 
modifying the drug absorption, reducing the metabolism, 
prolonging biological half-life, or reducing toxicity. 
Lipids that forming liposome can be from the natural or 
synthetic, as long as it is biocompatible and biodegradable. 
Besides, lipids are able to compartmentalize and solubilize 
both hydrophilic and hydrophobic materials by nature 
because they made up of lipids which are amphiphilic 
molecules (Çağdaş et al. 2014).
The stability in terms of the particle size and the 
ability to remain suspended in solution during prolonged 
storage is the important properties to be considered in 




order to achieve stability, one of the potential solutions 
by coating them with a polymer. Modification of the 
structure and surface of liposome have been discovered 
to generate liposomes with specific biological effects 
where it will contribute to the application of liposome in 
biomedicine (Li et al. 2019). There are various polymers 
that being investigated as a potential coating material for 
liposomes such as polyethylene glycol, alginate, dextran, 
pectin, gelatin, and chitosan.
In this study, chitosan, which is a linear biopolymer 
that composes of units of d-glucosamine and N-acetyl-
d-glucosamine that linked by a glycosidic ß (1-4) bond 
and it is derived from the partial deacetylation of chitin 
which is extracted from the crustacean shells (Baldrick 
2010) has been selected due to their natural occurrence 
and high biocompatibility. The molecular structure of the 
chitosan has an amino group (C2) and 2 hydroxyl group 
(C3 and C6) and the molecular weight ranges from 
10000 to 1 million Daltons (Sánchez-machado et al. 
2019). Furthermore, chitosan has good biodegradability 
and low toxicity that makes it suitable for being used in 
biomedical and pharmaceutical formulations especially 
in drug delivery (Wilson et al. 2010). 
Liposomes have been prepared by employing the dry 
lipid film hydration method, which is the most common 
technique to prepare liposomes. The stability of oleic acid 
liposomes as a result of the amount of coating material 
has been investigated in the aim to optimize the amount 
of LMWC in the formulation. A hydrophobic antifungal 
and antiviral drug, namely Itraconazole was encapsulated 
in the bilayer membrane of liposomes. Itraconazole 
is known as active triazole derivative drugs that have 
a broad spectrum of activity. This drug acts against 
commonly found pathogens like Candida spp. and also 
possesses as antiviral to inhibit viral infection such as 
Feline coronavirus (Takano et al. 2019) and Echovirus 
(Lee et al. 2017). There is an intravenous formulation of 
Itraconazole that had been developed by the researchers 
and this formulation had improved the absorption and 
bioavailability of the drug compared to the original 
capsules formulation (Ling et al. 2016). The compatibility 
of the drug with the liposome formulation has been 
studied. The in vitro drug release study was quantified 




Oleic acid and Itraconazole was purchased from Sigma 
(St. Louis, USA). Chloroform was purchased from 
Merck (Germany). Sodium hydroxide (NaOH) was 
purchased from Sigma-Aldrich (St. Louis, USA), while 
hydrochloric acid 37% and phosphate buffered saline 
tablet was purchased from Spectrum (New Brunswick, 
NJ). Immersion oil was purchased from Merck (Germany). 
Itraconazole and folinic acid calcium salt hydrate were 
purchased from Sigma (St. Louis, USA).
PREPARATION OF LMWC-OLEIC ACID LIPOSOME
Liposomes were prepared by using the thin-film hydration 
method. Oleic acid was weighed using a weighing 
balance (Denver Instrument, US) and dissolved in 5 mL 
chloroform. The mixture was homogenized using a JAC 
ultrasonic 1505 bath sonicator (Jeio Tech, Korea). The 
solution was transferred into 100 mL round bottom flask 
and the chloroform was removed by using Büchi® R114 
rotary evaporator (USA) equipped with a water bath under 
reduced pressure. The thin-lipid film was rehydrated 
with warm phosphate buffer saline (PBS) to the desired 
concentration. The pH of the solution was adjusted to 
pH7.4 by using 0.1 M hydrochloric acid (HCl) or sodium 
hydroxide (NaOH). Meanwhile, a different amount of 
LMWC was dissolved in PBS separately prior to coat the 
oleic acid liposome and stirred overnight.
MORPHOLOGICAL OBSERVATION VIA TRANSMISSION 
ELECTRON MICROSCOPY (TEM)
HR-TEM JEM2100F (JEOL, USA) equipped with Gatan 
software (Gatan Inc, USA) and an accelerating voltage of 
200 kV at Faculty of Medicine, University of Malaya had 
been used to observe the morphology of the liposome. 
A drop of the sample was introduced into a 400 mesh 
copper-coated carbon grid and excess liquid was removed 
using a clean filter paper. The grid was stained with 1% 
phosphotungstic acid and the excess staining agent was 
removed using a clean filter paper. The copper-coated 
carbon grid which contained the sample was air dried by 
placing it in the desiccator for 24 h.
ZETA POTENTIAL AND PARTICLE SIZE
The particle size and zeta potential were measured 
by using a Zetasizer NanoZS (Malvern Instruments 
Ltd., United Kingdom) equipped with 4 mW HE-NE 
laser at 633 nm in Fundamental and Frontier Science 
in Nanostructure Self Assembly (FSSA). 1 mL sample 
was added into four-sided clear polystyrene cuvette 
to measure the particle size while 1 mL was injected 
into polycarbonate with gold plated folded capillary cell 
electrode to measure the zeta potential. All measurements 
were carried out in triplicate at 25 ℃.
ENCAPSULATION EFFICIENCY
An appropriate amount of Itraconazole was dissolved 
in phosphate buffer pH7.4. The drug solutions were 
introduced to the round bottom flask that contains dry 
lipid film composed of oleic acid during the hydration. 
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The resulting mixture was adjusted to pH7.4 using an 
appropriate amount of 0.1 M hydrochloric acid (HCl) 
or sodium hydroxide (NaOH) and kept overnight. One 
mL sample was transferred to a Vivaspin centrifugal 
unit with a molecular weight cut off (MWCO) of 10 kDa 
(Satorius Stedim, Vilvoorde, Belgium) and centrifuged 
at 1500 rpm using velocity 18R refrigerated centrifuge 
(Dynamica Scientific Ltd., United Kingdom) for 15 min at 
25 ± 1 ℃. The absorbance of the free drug discarded was 
measured using a UV-vis spectrophotometer (Agilent 
Technologies, USA). The encapsulation efficiency (EE %) 
was calculated using (1):
(1)
where F is the amount of free drug; and T is the total 
amount of drug added into the oleic acid liposome.
IN-VITRO DRUG RELEASE STUDY
The in vitro release of Itraconazole from the LMWC-
coated oleic acid liposome was carried out using an 
automated Franz Diffusion Cell System (Hanson Research 
Co., USA). The receptor chambers were prefilled with 
media (PBS, pH7.4). The cellulose dialysis membranes 
5 kDa MWCO (The Nest Group Inc, USA) were placed 
on top of the receptor chambers followed by the donor 
chamber. An amount of 1 mL of LMWC-coated oleic 
acid liposome encapsulating Itraconazole was introduced 
into the donor chambers with stirring at 400 rpm and 
a controlled temperature of 37 ± 1 °C. The eluent was 
collected at 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 12.0, 16.0, 20.0, and 
24.0 h and quantified using calibration curve. 
RESULTS AND DISCUSSION
MORPHOLOGICAL OBSERVATION VIA TRANSMISSION 
ELECTRON MICROSCOPY (TEM)
The morphology of the liposome was observed by using 
TEM. The TEM images indicated that the liposomes 
formed were almost spherical in shape (Figure 1(a) and 
1(b)). The size of the oleic acid liposomes much smaller 
compared to the size of the liposome that coated with 
LMWC. This result was comparable to the particle 
size that was measured by using Zetasizer NanoZS. 
Furthermore, the irregular structure of LMWC-oleic 
acid liposome indicated that the existence of LMWC 
surrounding the liposomes. The polymer that coated the 
liposome would depend on the ability of the polymer to 
adhere to the lipid bilayer (Mady et al. 2009). 
AVERAGE PARTICLE SIZE AND ZETA POTENTIAL
Figure 2 shows the average particle size of liposomes as 
incubated for 28 days. The average particle size of oleic 
acid liposome coated with LMWC showed a larger size 
compared to the oleic acid liposome. The combination 
of adsorption coagulation and bridging between the 
chitosan and liposomes causes the interaction between 
them thus increasing the size of the liposome (Mady & 
Darwish 2010). The size of liposomes that coated with 
5 and 10 mg of LMWC did not show significant changes 
within 28 days of storage time. The particle size of 
liposome coated with 5 and 10 mg LMWC is 201.23 and 
238.43 nm, respectively. These results showed that 5 
and 10 mg of LMWC was sufficient to stabilize the oleic 
acid liposome. However, the average particle size of 
liposome that coated with 20 and 40 mg of LMWC was 
increased dramatically after the 21st day from 213.60 to 
518.13 nm and 206.87 to 762.53 nm, for 20 and 40 mg 
LMWC, respectively. This phenomenon has occurred may 
be due to the presence of excess chitosan that promotes 
the coagulation process might contribute to the increased 
of the liposome size (Tan & Misran 2013). However, on 
the 28th day, the particle size of 20 and 40 mg LMWC-
oleic acid liposome decreased. The formation of more 
chitosan layers on the surface of the liposome caused the 
weak interaction between the chitosan and the head group 
of the lipid which leads to the breakage of the liposome 
membrane. This phenomenon leads to the instability of the 
liposome and decreased particle size (Mertins & Dimova 
2013).
The surface modification of oleic acid liposome by 
coating with LMWC was evaluated by comparing the zeta 
potential on the 1st and 28th day. Table 1 shows that the 
zeta potential of oleic acid and LMWC-coated oleic acid 
was negatively charged. On day 1, the oleic acid liposome 
and the liposome that contained 5 mg LMWC resulted in 
the most negative zeta potential. Besides, the increasing 
amount of LMWC added to the oleic acid liposome had 
increased the zeta potential from -64.8 to -32.7 mV. The 
elevated zeta potential was due to the condensed chitosan 
that adsorbed to the liposomal surface since chitosan 
carriers a positive charge. (Mady & Darwish 2010). On 
the 28th day, the most negative zeta potential was oleic 
acid liposome and increased with an increasing amount 
of LMWC added to the oleic acid liposome. Increased zeta 
potential resulting in greater repulsion between particles, 
thus lead to a more stable colloidal dispersion (Mady et 
al. 2009).
ENCAPSULATION EFFICIENCY
The liposome can carry both hydrophilic and hydrophobic 
drugs which can increase the effectiveness of drugs 
towards the target cell. Furthermore, the closed structure 
of the vesicles which consist of one or more lipid bilayers 
that surrounded the inner aqueous compartment allows 
both hydrophilic and lipophilic drugs to be effectively 
encapsulated (Jaafar-maalej et al. 2010). 
%𝐸𝐸𝐸𝐸 = [100 − (𝐹𝐹𝑇𝑇  × 100)] 
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Figure 3 shows the encapsulation efficiency of 
Itraconazole in a LMWC-oleic acid liposome. The LMWC-
oleic acid liposomes were successfully encapsulated 
more than 90% of Itraconazole that was introduced into 
the formulation. This is due to the hydrophobicity of 
Itraconazole will spontaneously embedded Itraconazole 
within the liposome bilayers (Jaafar-maalej et al. 2010; 
Toniazzo et al. 2017). The incorporation of LMWC 
in the formulation showed a minimal effect on the 
encapsulation efficiency of Itraconazole in the formulated 
liposomes, where it was 94% in oleic acid liposomes, and 
the highest was 96% when the amount of LMWC is 5 mg. 
IN-VITRO RELEASE STUDY OF ITRACONAZOLE
The drug release study was carried out on five different 
formulations that different amounts of LMWC added 
in the oleic acid liposomes. The studied formulas were 
selected to investigate the impact of LMWC-coated oleic 
acid on drug release. Figure 4 shows the cumulative release 
of Itraconazole into the diffusion cells. In vitro release of 
bare Itraconazole after 24 h was 70.3% and significantly 
reduced to 2.6% in oleic acid liposomes. Incorporation 
of LMWC in the formulation affecting the in vitro release 
of Itraconazole. The result obtained might be attributed to 
the disruption of the lipid bilayer membrane, the structure 
and fluidity of the lipid bilayers that further effects the 
release of the drug from the liposomes (Hardiansyah et 
al. 2017). Formulation with 5 mg LMWC showed the 
least release at 3.7% after 24 h while formulation with 10 
mg LMWC showed the highest in vitro release at 27.1%. 
This showed that the incorporation of LMWC promoted 
the release of Itraconazole to the environment. Other than 
that, the permeability of the liposome by the addition of the 
polymer could promote the diffusion of the hydrophilic 
drug more favorable which made the release was higher 
(Suk & Misran 2017). However, the drop in the cumulative 
in vitro release of Itraconazole has occurred with the 




























(a) Oleic acid liposome (b) chitosan-oleic acid liposome 
FIGURE 1. TEM micrograph of (a) oleic acid liposome and (b) LMWC-
oleic acid liposome. The scale was 200 nm
FIGURE 2. The average particle size of LMWC-oleic acid liposomes at 
25 °C. The amount of LMWC added to oleic acid liposome 
0 
 verage particle size of LMWC-oleic acid liposomes at 25 °C. The amount of LMWC added to oleic acid liposome 0 
(■), 5 (  ), 10 (  ), 20 (  ), and 40 mg (  ) 
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further addition of LMWC, which may be due to the 
concentrated polymeric chain of LMWC at the surface 
FIGURE 3. Encapsulation Efficiency (%) of Itraconazole at different 
amounts of LMWC added into the oleic acid liposome. Measurement was 
taken in triplicate with a standard deviation of less than 1.0
FIGURE 4. In vitro release study of Itraconazole from LMWC-oleic acid 
liposome. Measurement was taken in triplicate with a standard deviation 
of less than 1.0
of liposomes became a protective barrier that prevents 
Itraconazole from released into the environment. 
TABLE 1. Zeta potential of LMWC-oleic acid liposome
Amount of LMWC added into the oleic acid 
liposome (mg)
Average zeta potential (mV)
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CONCLUSION
The oleic acid liposomes coated with different amounts 
of LMWC were successfully prepared by employing a 
thin lipid hydration method. It has been demonstrated 
that oleic acid liposome added with 5 mg LMWC was 
the best formulation due to its stability where the particle 
size and zeta potential are 201.23 nm and -51.4 mV, 
respectively. Based on the micrograph obtained from 
the TEM, the LMWC-oleic acid liposomes formed almost 
spherical in shape. The high encapsulation efficiency of 
Itraconazole and reduced drug release profile showed a 
slow-released where less than 40% of drugs released 
after 24 h. These data demonstrated that LMWC-liposome 
interaction had affected the stability of liposome thus this 
invention could be useful for delivering hydrophobic 
active ingredients. The LMWC-oleic acid liposome 
could be further investigated as an effective and potential 
intravenous drug delivery.
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